Cliramitug

Monoclonal antibody

Also known as ALXN2220, NI006

Phase 3underway

Evidence outlook · registrational

Transthyretin Amyloidosis with Cardiomyopathy: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2027-12-06.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Transthyretin Amyloidosis with Cardiomyopathy
NCT07789483 · Alexion Pharmaceuticals, Inc.
2027-11-23 – 2030-07-11 · Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
What this study did
NCT06183931 · Alexion Pharmaceuticals, Inc.
2024-01-11 – 2028-04-05 · Transthyretin Amyloid Cardiomyopathy
What this study did
Phase 2 (2)
Transthyretin Amyloidosis with Cardiomyopathy
NCT07608354 · AstraZeneca
2026-06-11 – 2029-02-06 · Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
What this study did
NCT07213583 · Neurimmune AG
2025-08-28 – 2026-10-31 · Amyloid Transthyretin Cardiomyopathy
What this study did
Phase 1 (1)
Other / comorbidity
NCT04360434 · Neurimmune AG
2020-02-10 – 2023-07-26 · Amyloid Transthyretin Cardiomyopathy
What this study did

Competitive landscape

This mechanism is crowded: 8 other tracked programmes target it, 5 of them ahead of this one.

This drug's own stage for Transthyretin Amyloidosis with Cardiomyopathy: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Cliramitug: this drugPhase 3Monoclonal antibodyTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication
Acoramidis (Attruby)ApprovedSmall moleculeTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication
Patisiran (ONPATTRO)
Approved(overall)
RNA / oligonucleotideTransthyretin (TTR)
Reliable signal(overall)
NCT03997383: Change From Baseline at Month 12 in Six-Minute Walk Test (6-MWT) (Baseline, Month 12): Placebo (DB)/Patisiran (OLE) -21.345 meters (95% CI -68.268 to 12.75) | Patisiran (DB+OLE) -8.15 meters (95% CI -54.651 to 29.51)
Vutrisiran (AMVUTTRA)ApprovedRNA / oligonucleotideTransthyretin (TTR)Reliable signal
NCT04153149: Composite of all-cause mortality and recurrent cardiovascular events: overall population HR 0.718 (95% CI 0.555 to 0.929), p=0.0118; vutrisiran monotherapy subgroup HR 0.672 (95% CI 0.487 to 0.929), p=0.0162
Inotersen (Tegsedi)
US approval withdrawn(overall)
RNA / oligonucleotideTransthyretin (TTR)
Reliable signal(overall)
No reviewed efficacy summary in this indication
Coramitug
Phase 3(overall)
Monoclonal antibodyTransthyretin (TTR)
not yet graded(overall)
No reviewed efficacy summary in this indication
Eplontersen (Wainua)Phase 3RNA / oligonucleotideTransthyretin (TTR)Partial signal
NCT04136171: CARDIO-TTRansform primary composite: rate ratio 0.89 (95% CI 0.73 to 1.09), P=0.28; no significant reduction. missed
Nexiguran ZiclumeranPhase 3Gene therapy / editingTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication
NucresiranPhase 3RNA / oligonucleotideTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Cliramitug to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Phase 3Transthyretin Amyloidosis with CardiomyopathyActive not recruiting
Est. primary completion 2027-12-06 · NCT06183931 · CT.gov ↗
What to watch
2029 (1)
February 2029 (1)
Phase 2Transthyretin Amyloidosis with CardiomyopathyActive not recruiting
Est. primary completion 2029-02-06 · NCT07608354 · CT.gov ↗
What to watch
2030 (1)
July 2030 (1)
Phase 3Transthyretin Amyloidosis with CardiomyopathyNot yet recruiting
Est. primary completion 2030-07-11 · NCT07789483 · CT.gov ↗
What to watch

See the full readout calendar ↗